This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of formula I



I

in which

R^1 and R^2 are each, independently of one another, H, OH, OR^8, $-SR^8$, $-SOR^8$, $-SO_2R^8$ or Hal,

R^1 and R^2 together are alternatively $-OCH_2O-$ or $-OCH_2CH_2O-$,

R^3 is H, $A''R^9$, $COA''R^9$, $COOA''R^9$, $CONH_2$, $CONHA''R^9$, $CON(A''R^9)(A'''R^9)$, NH_2, $NHA''R^9$, $N(A''R^9)(A'''R^9)$, $NCOA''R^9$ or $NCOOA''R^9$,

R^4 is H, $A''R^9$, $COA''R^9$, $COOA''R^9$, $CONH_2$, $CONHA''R^9$ or $CON(A''R^9)(A'''R^9)$,

B is an aromatic isocyclic or heterocyclic radical, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by R^5, R^6 and/or R^7,

X is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2, NH or $NA''R^9$,
1-7 H atoms may be replaced by F and/or Cl,
and/or 1 or 2 H atoms may be replaced by R^{11} and/or R^{12},

R^5, R^6 and R^7 are each, independently of one another, H, $A''R^9$, OH, $OA''R^9$, NH_2, $NHA''R^9$, $N(A''R^9)(A'''R^9)$, $NHCOA''R^9$, $NHCOOA''R^9$, $NHCONH_2$, $NHCONHA''R^9$, $NHCON(A''R^9)(A'''R^9)$, Hal, COOH, $COOA''R^9$, $CONH_2$, $CONHA''R^9$, $CON(A''R^9)(A'''R^9)$,



R^8 is A, cycloalkyl having 3-7 carbon atoms or alkylenecycloalkyl having 4-8 carbon atoms,

R^9 is H, COOH, COOA, $CONH_2$, CONHA, CONAA', NH_2, NHA, NAA', NCOA, NCOOA, OH, OA, $(CH_2)_n$-aryl or $(CH_2)_n$Het,

R^{10} is alkyl having 1-10 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylenecycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms,
in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2, NH, NMe, NEt and/or by -CH=CH- groups,
1-7 H atoms may be replaced by F and/or Cl,
and/or 1 H atom may be replaced by R^9,

R^{11} is H, A, COOA"R^9, $CONH_2$, CONHA"R^9, CON(A"R^9)(A'"R^9), NH_2, NHA"R^9, N(A"R^9)(A'"R^9), NCOA"R^9, NCOOA"R^9, OH or OA"R^9,

R^{12} is H, A, COOA"R^9, $CONH_2$, CONHA"R^9 or CON(A"R^9)(A'"R^9),

Y is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2, NH or NR^{10} and/or
1-7 H atoms may be replaced by F and/or Cl,

A and A' are each, independently of one another, alkyl having 1-10 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH_2 groups may be replaced by O,

S, SO, SO_2, NH or NR^{10} and/or

1-7 H atoms may be replaced by F and/or Cl,

or

aryl or Het,

A and A' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2, NH, NR^{10}, $NCOR^{10}$ or $NCOOR^{10}$,

A'' and A''' are each, independently of one another,

absent, alkylene having 1-10 carbon atoms, alkenylene having 2-8 carbon atoms or cycloalkylene having 3-7 carbon atoms,

in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2, NH or NR^{10} and/or

1-7 H atoms may be replaced by F and/or Cl,

A'' and A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH_2 groups may be replaced by O, S, SO, SO_2, NH, NR^{10}, $NCOR^{10}$ or $NCOOR^{10}$,

aryl is phenyl, naphthyl, fluorenyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, R^{14}, OR^{13}, $N(R^{13})_2$, NO_2, CN, $COOR^{13}$, $CON(R^{13})_2$, $NR^{13}COR^{13}$, $NR^{13}CON(R^{13})_2$, $NR^{13}SO_2A$, COR^{13}, $SO_2N(R^{13})_2$ or $S(O)_mR^{14}$,

R^{13} is H or alkyl having 1-6 carbon atoms,

R^{14} is alkyl having 1-6 carbon atoms,

Het is a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, R^{14}, OR^{13}, $N(R^{13})_2$, NO_2, CN, $COOR^{13}$, $CON(R^{13})_2$, $NR^{13}COR^{13}$, $NR^{13}CON(R^{13})_2$, $NR^{13}SO_2R^{14}$, COR^{13}, SO_2NR^{13} and/or $S(O)_mR^{14}$,

Hal is F, Cl, Br or I,

m is 0, 1 or 2, and

n is 0, 1, 2, 3 or 4,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

2. (Previously Presented) A compound according to Claim 1, in which

R^1 and R^2 are each, independently of one another, H, methoxy, ethoxy, benzyloxy, propoxy, isopropoxy, difluoromethoxy, F, Cl, cyclopentyloxy, cyclohexyloxy or cycloheptyloxy,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

3. (Previously Presented) A compound according to Claim 1, in which

R^1 and R^2 are each, independently of one another, methoxy, ethoxy, propoxy, isopropoxy, cyclopentyloxy or F,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

4. (Previously Presented) A compound according to Claim 1, in which

R^1 is 4-methoxy, and

R^2 is 3-ethoxy,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

5. (Previously Presented) A compound according to Claim 1,

in which

R^4 is H,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

6. (Previously Presented) A compound according to Claim 1,

in which

R^3 is H, $COO(CH_2)_n$-aryl, COA"H, COOA"H, A"NAA', A"-aryl or A"Het,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

7. (Previously Presented) A compound according to Claim 1,

in which

X is methylene, ethylene, propylene or butylene,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof

8. (Previously Presented) A compound according to Claim 1,

in which

B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolinyl, oxazolinyl, thiazolinyl, pyrazolinyl, imidazolinyl, naphthyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by OH, OA, NH_2, NAA', O-alkylene-NAA' or O-alkylene-OH,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

9 (Previously Presented) A compound according to Claim 1,

in which

B is phenyl which is unsubstituted or monosubstituted by OR^{13}, $N(R^{13})_2$, O-alkylene-$N(R^{13})_2$ or O-alkylene-OH, or unsubstituted pyridyl,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

10. (Previously Presented) A compound according to Claim 1,

in which

R^1 and R^2 are each, independently of one another, H, methoxy, ethoxy, benzyloxy, propoxy, isopropoxy, difluoromethoxy, F, Cl, cyclopentyloxy, cyclohexyloxy or cycloheptyloxy,

R^1 and R^2 together are alternatively $-OCH_2O-$ or $-OCH_2CH_2-O-$,

R^3 is H, A"R^9, COA"R^9, COOA"R^9, $CONH_2$, CONHA"R^9, CON(A"R^9)(A'"R^9), NH_2, NHA"R^9, N(A"R^9)(A'"R^9), NCOA"R^9 or NCOOA"R^9,

R^4 is H,

X is methylene, ethylene, propylene or butylene,

A" and A'" are each, independently of one another, absent or alkylene having 1, 2, 3 or 4 carbon atoms, and

R^9 is H, $(CH_2)_n$-aryl or $(CH_2)_n$Het,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

11. (Previously Presented) A compound according to Claim 1,

in which

R^1 and R^2 are each, independently of one another, H, methoxy, ethoxy, benzyloxy, propoxy, isopropoxy, difluoromethoxy, F, Cl, cyclopentyloxy,

cyclohexyloxy or cycloheptyloxy,

R^1 and R^2 together are alternatively $-OCH_2O-$ or $-OCH_2CH_2-O-$,

R^3 is H, $A"R^9$, $COA"R^9$, $COOA"R^9$, $CONH_2$, $CONHA"R^9$, $CON(A"R^9)(A'"R^9)$, NH_2, $NHA"R^9$, $N(A"R^9)(A'"R^9)$, $NCOA"R^9$ or $NCOOA"R^9$,

R^4 is H,

X is methylene, ethylene, propylene or butylene,

A" and A'" are each, independently of one another, absent or alkylene having 1, 2, 3 or 4 carbon atoms,

R^9 is H, $(CH_2)_n$-aryl or $(CH_2)_n$Het,

aryl is phenyl, naphthyl, fluorenyl or biphenyl, each of which is unsubstituted or monosubstituted by OR^{13},

R^{13} is H or alkyl having 1-6 carbon atoms,

Het is pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolinyl, oxazolinyl, thiazolinyl, pyrazolinyl, imidazolinyl, naphthyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl, and

B is phenyl which is unsubstituted or monosubstituted by OR^{13}, $N(R^{13})_2$, O-alkylene-$N(R^{13})_2$ or O-alkylene-OH, or unsubstituted pyridyl,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

12. (Previously Presented) A compound according to Claim 1,

in which

R^1 and R^2 are each, independently of one another, methoxy, ethoxy, propoxy or isopropoxy,

R^3 is H, fluorenylmethyloxycarbonyl, acetyl, tert-butyloxycarbonyl, benzyloxycarbonyl, N,N-dimethylaminoethyl, benzyl or pyridylmethyl,

R^4 is H,

X is methylene, ethylene, propylene or butylene,

R^{13} is H or alkyl having 1-6 carbon atoms,

Het is pyridyl, and

B is phenyl which is unsubstituted or monosubstituted by OR^{13}, $N(R^{13})_2$, O-alkylene-$N(R^{13})_2$ or O-alkylene-OH, or unsubstituted pyridyl;

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

13. (Original) A compound according to Claim 1, which is

a) benzyl {1-(1S)-(4-tert-butoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}carbamate,

b) benzyl {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-1-(1S)-(4-hydroxybenzyl)-2-oxoethyl}carbamate,

c) 2-(2S)-amino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-[4-(2-hydroxyethoxy)phenyl]propan-1-one,

d) 3-[4-(2-dimethylaminoethoxy)phenyl]-2-(2S)-(2-dimethylaminoethylamino)-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]propan-1-one,

e) 2-(2S)-amino-3-[4-(2-dimethylaminoethoxy)phenyl]-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]propan-1-one,

f) 9H-fluoren-9-ylmethyl {1-(1S)-(4-tert-butoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}carbamate,

g) 2-(2S)-amino-3-(4-tert-butoxyphenyl)-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]propan-1-one,

h) 2-(2S)-amino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-(4-hydroxyphenyl)propan-1-one,

i) 2-(2S)-benzylamino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-(4-hydroxyphenyl)propan-1-one,

j) 1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-(4-hydroxyphenyl)-2-(2S)-[(pyridin-4-ylmethyl)amino]propan-1-one,

k) tert-butyl {1-(1R)-(4-methoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}carbamate,

l) tert-butyl {1-(1S)-(4-methoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}carbamate,

m) N-{1-(1S)-(4-tert-butoxybenzyl)-2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}acetamide,

n) N-[2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-1-(1S)-(4-hydroxybenzyl)-2-oxoethyl]acetamide,

o) tert-butyl {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxo-1-(1R)-(pyridin-3-ylmethyl)ethyl}carbamate,

p) 2-(2R)-amino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-

3-pyridin-3-ylpropan-1-one,

q) tert-butyl {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxo-1-(1R)-(pyridin-4-ylmethyl)ethyl}carbamate, or

r) 2-(2R)-amino-1-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-3-pyridin-4-ylpropan-1-one,

or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof.

14. (Cancelled)

15. (Previously Presented) A process for preparing a compound of claim 1 or a salt or solvate thereof, comprising

a) reacting a compound of formula II



II

in which

R^1 and R^2 are as defined in Claim 1,

with a compound of formula III



III

in which

L is Cl, Br, I or a free or reactively functionally modified OH group,

and R^3, R^4, X and B are as defined in Claim 1,

with the proviso that any further OH and/or amino group present is protected,

and subsequently, optionally, a protecting group is removed,

or

b) one or more radicals R^1, R^2, R^3, R^4 and/or B in a compound of the formula I are

converted into one or more other radicals R^1, R^2, R^3, R^4 and/or B by

i) cleaving an ether or ester,

ii) alkylating or acylating an OH function,

iii) reductively alkylating an amino group,

and/or a basic compound of formula I is converted into one of its salts by treatment with an acid.

16. (Previously Presented) A pharmaceutical composition comprising at least one compound according to Claim 1 or a pharmaceutically acceptable salt, prodrug, solvate or a stereoisomer thereof and one or more excipients and/or adjuvants.

17-26 (Cancelled)